TRIPLE NEGATIVE BREAST CANCER (TNBC)
Clinical trials for TRIPLE NEGATIVE BREAST CANCER (TNBC) explained in plain language.
Never miss a new study
Get alerted when new TRIPLE NEGATIVE BREAST CANCER (TNBC) trials appear
Sign up with your email to follow new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo attack on tough breast cancer
Disease control Recruiting nowThis study is testing different ways to combine radiation therapy with immunotherapy drugs to treat advanced triple-negative breast cancer (TNBC), a hard-to-treat form. It will enroll 60 patients who have not yet received chemotherapy for their advanced disease. The goal is to fi…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Scientists test ultrasound & immune therapy combo to fight tough breast cancer
Disease control Recruiting nowThis study is testing whether using focused ultrasound to destroy breast tumors, combined with immunotherapy drugs that activate the body's defenses, can make standard chemotherapy more effective against triple-negative breast cancer. About 40 women with early-stage triple-negati…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New hope for tough breast cancer: major trial tests novel drug
Disease control Recruiting nowThis study is comparing a new drug called ESG401 to standard chemotherapy as the first treatment for advanced triple-negative breast cancer that cannot be removed by surgery. It will involve about 504 patients whose cancer has spread or come back. The main goals are to see if ESG…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
First-in-Human trial tests new weapon against tough cancers
Disease control Recruiting nowThis is the first study in people to test a new drug called XB010 for advanced solid tumors that have stopped responding to other treatments. The main goals are to find a safe dose and see if the drug, given alone or with another cancer drug, shows early signs of fighting the can…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New pill targets tough cancers in early human trial
Disease control Recruiting nowThis early-stage study is testing a new oral drug called JAB-2485 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shows early signs of helping shrink tumors in cancers like certai…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Gut bacteria boost tested in fight against aggressive breast cancer
Disease control Recruiting nowThis study is testing whether adding an oral probiotic supplement called Biolosion to standard chemotherapy before surgery is more effective for women with triple-negative breast cancer. Researchers want to see if the probiotic helps the body respond better to treatment, aiming f…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
New hope for Tough-to-Treat breast cancer
Disease control Recruiting nowThis study is testing whether an experimental drug called tenalisib can help control metastatic triple-negative breast cancer. It's for patients who have already tried 1-3 other treatments that didn't work well enough. Researchers will measure how many patients benefit from the d…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Rhizen Pharmaceuticals SA • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
AI-Designed drug trial opens for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing a new drug called GTAEXS617 in people with advanced solid tumors that have stopped responding to standard treatments. Researchers want to find the safest dose and see if the drug can shrink tumors in cancers like lung, pancreatic, ovarian, and breast cancer.…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
First patients to try new pill targeting Hard-to-Treat cancers
Disease control Recruiting nowThis is the first study in people testing a new oral medication called NKT5097 for adults with advanced or metastatic solid tumors, with a focus on certain breast, ovarian, and uterine cancers. The main goals are to find a safe dose, see how the body processes the drug, and check…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New hope for breast cancer patients: testing Next-Generation targeted drugs after initial treatment fails
Disease control Recruiting nowThis study is testing whether different antibody-drug conjugates (ADCs) can help control advanced breast cancer in patients who have already received similar treatments. The trial will enroll 160 participants with metastatic breast cancer to test several experimental ADCs and see…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Blood test trial aims to catch breast Cancer's return before scans can
Disease control Recruiting nowThis study is for people with a high-risk type of breast cancer who have had surgery but still have some cancer cells left. Researchers want to see if a special blood test can find signs that the cancer is coming back before it shows up on standard scans. If the blood test is pos…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New pill targets immune system to fight tough cancers
Disease control Recruiting nowThis is a first-in-human study testing a new oral drug called NX-1607 in adults with advanced cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the body handles the drug, both alone and combined with a common chemot…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New cancer drug trial tests experimental treatment for tough tumors
Disease control Recruiting nowThis early-stage study is testing whether an experimental drug called NRM-823 is safe and can help control advanced cancers that have stopped responding to standard treatments. Researchers will give NRM-823 alone and combined with immunotherapy to about 150 adults with various so…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Normunity AccelCo, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Scientists test 'Living Drug' that hunts breast cancer cells
Disease control Recruiting nowThis study is testing a new type of treatment called CAR-NK cell therapy for people with advanced breast cancer that has stopped responding to standard treatments. Doctors will collect a patient's own natural immune cells, modify them in a lab to better recognize and attack cance…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New cancer drug enters first human trials for Tough-to-Treat tumors
Disease control Recruiting nowThis is the first study in people to test a new drug called PQ203 for advanced solid tumors, including a hard-to-treat type of breast cancer. The main goals are to check if the drug is safe and to find the best dose for future studies. About 80 adults who have run out of standard…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: ProteinQure Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New 'Tumor-Seeking' radiation drug enters human trials for tough cancers
Disease control Recruiting nowThis study is testing a new type of cancer drug that delivers radiation directly to tumors by targeting a protein called Nectin-4. It aims to find a safe and effective dose for patients with advanced solid cancers who have already tried other treatments. The trial will first dete…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for Tough-to-Treat breast cancer: major trial tests promising drug combo
Disease control Recruiting nowThis large, late-stage study is testing whether adding an investigational drug called AK112 to standard chemotherapy works better than chemotherapy alone for people with advanced triple-negative breast cancer. It aims to see if the combination can better control the cancer and he…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Targeted radiation therapy tested for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing a two-part approach for people with advanced cancers that cannot be removed by surgery. First, a special imaging scan is used to see if a tumor has a specific target. If it does, a targeted radiation treatment is given to try to control the cancer. The main …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: ITM Oncologics GmbH • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for Tough-to-Treat breast cancer: early trial tests promising drug
Disease control Recruiting nowThis study is testing a new drug called MR001 for people with advanced triple-negative breast cancer that has continued to grow despite previous treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
New hope for aggressive breast cancer: trial tests powerful drug combo before surgery
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug called QL1706 to standard chemotherapy works better when given before surgery for triple-negative breast cancer. It will involve 30 patients with stage II or III cancer who have not yet started treatment. The main goal…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Affiliated Hospital of Nantong University • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
Scientists test 'Switchable' cell therapy to fight advanced breast cancer
Disease control Recruiting nowThis is an early study to test the safety of a new two-part treatment for people with advanced breast cancer that has spread or cannot be removed by surgery. The treatment involves giving patients their own modified immune cells (CLBR001), followed by a biologic drug (ABBV-461) t…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Mar 09, 2026 14:24 UTC
-
Scientists collect cancer cells to build future personalized treatments
Knowledge-focused Recruiting nowThis study is preparing for future cancer treatment trials by collecting information and materials from patients. Researchers will analyze tumor tissue from people with advanced solid tumors and collect their white blood cells through a procedure called apheresis. The collected c…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Apr 03, 2026 21:25 UTC